plicamycin has been researched along with Leukemia, Promyelocytic, Acute in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fraizer, GC; Ghimirey, N; Kuerbitz, SJ; Moazam, M; Pandey, S | 1 |
Cotter, TG; Duverger, V; England, K; Hayes, I; Murphy, AM; Murphy, FJ; Sheehan, D | 1 |
2 other study(ies) available for plicamycin and Leukemia, Promyelocytic, Acute
Article | Year |
---|---|
WT1 regulates cyclin A1 expression in K562 cells.
Topics: Adolescent; Binding Sites; Cell Proliferation; Cell Survival; Child; Child, Preschool; Curcumin; Cyclin A1; Female; Gene Expression Regulation, Neoplastic; Humans; Infant; K562 Cells; Leukemia, Promyelocytic, Acute; Male; Plicamycin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Promoter Regions, Genetic; Up-Regulation; WT1 Proteins | 2019 |
The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF).
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Carrier Proteins; Drug Resistance, Neoplasm; fas Receptor; Fas-Associated Death Domain Protein; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Promyelocytic, Acute; Plicamycin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2004 |